Although serum creatinine remains the most commonly used renal marker for estimation of GFR, it is substantially dependent on race, sex, and body composition, which limits its clinical reliability (1, 2 ) . Cystatin C is a cysteine protease inhibitor with a molecular mass of 13 kDa that is produced by all nucleated cells in the body at a constant rate less affected by sex, race, and body composition than serum creatinine (3 ) . Thus, cystatin C has been proposed as a glomerular filtration rate (GFR) 1 marker (4 ), particularly in patient populations with chronic diseases that change body composition (5, 6 ) . We performed a method comparison of 4 automated cystatin C assays: Siemens N Latex Cystatin C on a BNII, Roche Gentian Cystatin C and Genzyme Cystatin C on a Roche Cobas c501, and Tosoh ST AIA-PACK Cystatin C on a Tosoh AIA-600II (Table 1 ). The US Food and Drug Administration (FDA) has approved the first 3 assays, whereas the Tosoh assay is currently for investigational use only.
Ethics approval was obtained from the Johns Hopkins Internal Review Board. For patient comparison studies, we selected 102 specimens; approximately half of the samples with creatinine values lower than the upper limit of the reference interval [Ͻ1.3 mg/dL (0.115 mmol/L) for men, Ͻ1.2 mg/dL (0.106 mmol/L) for women, n ϭ 58], and half above the upper limit of the reference range [Ͼ1.3 mg/dL (0.115 mmol/L) for men, Ͼ1.2 mg/dL (0.106 mmol/L) for women, n ϭ 44]. We prepared serum pools with low, medium, and high concentrations of cystatin C by pooling patient serum with low (Ͻ1.2 mg/dL, Ͻ0.106 mmol/L), medium (3-7 mg/dL, 0.265-0.619 mmol/L), and high (Ͼ10 mg/dL, Ͼ0.884 mmol/L) concentrations of creatinine. Specimens were stored refrigerated for no more than 1 week after collection, and then stored at Ϫ20°C until analysis.
Assays were evaluated following guidelines from the Clinical and Laboratory Standards Institute (CLSI). We evaluated limit of blank (LoB), limit of detection (LoD) and limit of quantification (LoQ) following guideline EP17-A (7 ) and total imprecision following a modification of guideline EP15-A2 (8 ) . Using single lots of reagents, we analyzed 2 replicates of the 3 serum pools twice per day for 5 days, with at least 2 h separating the daily runs. We evaluated linearity following guideline EP6-A (9 ). We prepared serial 10% dilutions (e.g., 90:10, 80:20) of the high concentration serum pool using cystatin C-free serum (HyTest Ltd.) as diluent. We measured these samples in triplicate and plotted the measured value against the expected value (mean of 100% serum pool ϫ dilution factor) using EP Evaluator (David G. Rhodes Associates, Inc.). We calculated percent recovery as the measured concentration divided by the expected concentration multiplied by 100% and compared results from each assay on 102 patient samples following guideline EP9-A2 (10 ). For data analysis, we used EP Evaluator release 8 or Microsoft Excel (LoD only).
The LoD and LoQ values demonstrated the most variability among assays (Table 2) . Although the actual values for LoD and LoQ showed differences of up to 10-fold, all ewre below the quoted reference intervals for patient specimens (0.53-0.95 mg/L by Siemens, 0.47-1.09 mg/L by Roche, 0.61-1.17 mg/L by Genzyme, and 0.52-0.97 mg/L by Tosoh). Therefore we considered all assays to have sufficient analytic sensitivity for clinical use. Compared with the manufacturer's specifications, the total CVs observed by us were generally higher, the largest discrepancy being observed with the Genzyme assay (8.9% vs 2.3% for the low-concentration cystatin C pools, 3.7% vs 1.3% for the medium-concentration pools, and 9% vs 2.4% for the high-concentration pools) ( Table 1) . Because the serum pools used in this study were different from the pools used by the manufacturer, we did not calculate statistical significance of the observed differences.
In the linearity study (Table 1) , the Roche assay tended to overrecover, especially at low cystatin C concentrations. There was a gradual increase in recovery, from 100% on the highest sample (assigned value 5.869 mg/L, mean of triplicate measurement) to 142% on the lowest sample (assigned value 0.5869 mg/L, as 10% of the high-concentration pool). Regression analysis of the recovery data suggested both proportional and constant bias by the Roche assay, with a slope of 0.945 and an intercept of 0.55. The other 3 assays demonstrated a mean recovery close to 100% (Siemens, 100.05%, range 96.2%-103.4%; Genzyme, 98.49%, range 97.4%-101.7%; Tosoh, 100.67%, range 98.1%-103.2%) with slopes close to 1 and intercepts close to 0.
For method comparison, we compared the results on 102 patient samples from each method with the Siemens assay, since this assay is the most widely used based on 2008 College of American Pathologists survey participants (40 of 48 laboratories submitted results using the Siemens assay) and was also the first commercial cystatin C assay to obtain FDA approval. The equations (Fig. 1 ) obtained using Deming regression were y ϭ 1.184x ϩ 0.089, S y.x ϭ 0.246, R ϭ 0.987 (Genzyme vs Siemens); y ϭ 0.937x ϩ 0.231, S y.x ϭ 0.134, R ϭ 0.995 (Roche vs Siemens); and y ϭ 1.010x ϩ 0.216, S y.x ϭ 0.135, R ϭ 0.997 (Tosoh vs Siemens). The Genzyme assay appeared to give higher results than the Siemens assay, which is consistent with a higher reference interval specified by the manufacturer (0.61-1.17 mg/L by Genzyme, 0.53-0.95 mg/L by Siemens) ( Table 1) . Based on a previous publication evaluating the Siemens (x) and the Genzyme (y) cystatin C assays, a linear regression of y ϭ 0.975x ϩ 0.197, R ϭ 0.995 was reported (S y.x was not provided) (11 ) . In this case, a large positive intercept contributed to the higher results by the Genzyme assay. We are unclear about the cause of this difference on regression analysis, but 1 possibility may be that 1 or both manufacturers has changed calibration or reagent formulation in the interval between evaluations.
Although all assays were acceptable for clinical use according to commonly accepted criteria, their diagnostic performances were not optimal. Concerns for different assays include imprecision observed for the Genzyme assay, overrecovery at low cystatin C concentrations by the Roche assay, and assay specific differences in the patient comparison studies. The latter situation means that assay-specific cystatin C-based GFR-prediction equations are required. This problem might be solved if the assays' calibration can be standardized using the international cystatin C calibrator now being developed (12 ) . Factors such as available instrumentation and cost of reagents may also contribute to the suitability of each assay for a given laboratory. The Siemens N Latex cystatin C assay is a nephe- lometric method, and the Tosoh ST AIA-PACK cystatin C assay is a 2-site immunometric assay; both must be run on specific immunoassay instruments. The Roche Gentian cystatin C and the Genzyme cystatin C assays are particle-based immunoassays that may be run on automated chemistry analyzers and therefore are less restricted with respect to instrumentation.
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